No abstract available.
Malaria*

No abstract available.
Malaria*

No abstract available.
Malaria*

Background: Forest malaria is one of the challenges faced by the Malaria Control Program in Vietnam. Objectives: (1). To evaluate the malaria prevalence among forest goers, (2). To study the efficacy of insecticide-treated hammock net (ITHNs) in malaria prevention for forest goers. Subject and method: The descriptive epidemiological intervention study on the effect of ITHNs in forest malaria control has been carried out in Ninh Thuan in 2005 \ufffd?2006. Results: Malaria prevalence among forest goers was very high: Clinical malaria: 15.5%, enlarged spleen: 7.0%, confirmed cases: 13.3% and asymptomactic cases: 74%. Age, sex, ethnic, low educated levels, low income, less use of mosquito-nets and poor house condition were considered as risk factors in malaria infection, especially for people who spent much time in the forest. ITHNs were effective in prevention of malaria infection, the malaria morbidity was decreased after 2 years of application (reduced from 31 % to 14% for prevalence, and from 274/1000 population to 161/1000 population for incidence), and the morbidity rate was lower than that in the group of people who did not use ITHNs. Conclusion: For the entomological survey, it is found that Anopheles density reduced in the group of people prevented by ITHNs. The residual of insecticide on the hammock net was decreased after 2 years utilization.\r\n', u'\r\n', u'\r\n', u'
Malaria

Background: Malaria remains to be one of the major health problems in tropical areas of the world. It puts at least one-third of the world population at risk of infection and afflicts over 200 million people worldwide, approximately 7000 of whom are Filipinos. In spite of available drugs, malarial chemotherapy is still insufficient. The increased resistance of Plasmodium falciparum strains to existing antimalarial drugs prompts the discovery of new therapeutic agents for malaria. Objective: This study aimed to uncover, through molecular docking technique, new chemical entities that can be developed as new drugs for malaria. Methodology: In this study, 2,527 approved and 5,755 experimental drugs from DrugBank and 4,687 natural compounds from Analyticon MEGx database were docked against Plasmodium falciparum aspartate transcarbamoylase (PfATC) and oritidine-5'-monophosphate decarboxylase (PfOMPDC), two key enzyme targets involved in the de novo biosynthesis pathway of the pathogen. Results: A total of 39 compounds (1 approved drug, 19 experimental drugs, 19 natural products) had larger binding energy (BE) values than the known ligands 2,3-naphthalenediol (BE = -7.0 kcal/mol) and uridine 5- PfATC monophosphate (BEPfOMPDC = -9.0 kcal/mol). The top 3 hits were natural products: dihydrotrichotetronine (BEPfATC = -21 kcal/mol, BE = -18 kcal/mol), ginkgolide A (BE = -19 kcal/mol, BE = -15 kcal/mol), and PfOMPDC PfATC PfOMPDC ginkgolide C (BE = -16 kcal/mol, BE = -16 kcal/mol). Conclusion Based on calculated binding energy and ADMET properties, dihydrotrichotetronine, ginkgolide A, and ginkgolide C are the best natural product candidates for further development as dual inhibitors for both PfATC and PfOMPDC enzymes. Furthermore, myricetin (BE = -9 kcal/mol, BE = -10 kcal/mol) and PfATC PfOMPDC tolcapone (BE = -9.1 kcal/mol, BE = -9.2 kcal/mol) may also be repurposed as anti-malarial drugs.
Malaria

Mixed falciparum-vivax infection accounts for 5% of all malaria cases seen in endemic region. However, a larger proportion of mixed malaria cases develop cerebral complication. We report one case of mixed infection resulted in cerebral malaria.
Coinfection ; Malaria* ; Malaria, Cerebral

Sensitivity and specificity of the Asan Easy Malaria P.f/P.v tests (made by Asan Korean Company) in the diagnosis of P. falciparum and P.vivax malaria was investigated compared to Giemsa microscopy and re-checked by PCR technique. A total of 283 tests were conducted in the provinces of Lai Chau, Quang Binh and Binh Phuoc, and 90 other ones were carried out with cultured P. falciparum at the laboratories of the National Institute of Malariology, Parasitology and Entomology. The different results were found with two method as 111 positive cases were confirmed by Giemsa staining (59 P.falciparum and 54 P.vivax), while only 94 positive tests (53 P.falciparum and P.vivax) were determined by Asan. The samples with different results by two methods were re-cheked by PCR technique for confimation. The sensitivity and specificity of Asan tests in Plasmodium species detection were 97.8 and 89.9%, respectively, in general, and 99.0% and 91.2% in diagnosis of P falciparum, and 75.9% and 97% of P. vivax, in particular. However, in the following-up period (2-3 days), both methods showed the same results of parasite re-examination
Malaria ; Diagnosis ; Malaria, Vivax

Objective and methods: 83 patients infected with P.vivax malaria were divided randomly into two groups. 51 patients were treated with CV8 and 32 patients were treated with Chlo + Pri. Results: The mean time for disolving fever was 20.1 hours for CV8 group and 21.0 hours for Chlo + Pri group, the difference has no statistic significance with P>0.05. The mean parasite clearance time was 30.3 hours and 31.0 hours for CV8 and Chlo + Pri groups. respectively, the difference has no statistic significance with P>0.05. The relapse parasite rate was 3.9 % in CV8 group, highter than that in Chlo + Pri group (3.1%) of , the difference has no statistic significance with P>0.05. Conclusion: CV8 can be used for P. vivax malaria patients in the hyper-epidemic remote areas.
Malaria ; Primaquine ; Malaria ; Falciparum

224 patients with uncomplicated P. falciparum malaria were randomly devided into two groups receiving CV8 treatment (123 patients) and artesunate+primaquine (As+Pri) (101 patients). Results: The lately recurrence rate of CV8 treatment was 3.3% and of As+Pri was 17.8%, the difference had statistic significance (p<0.05). Mean time for fever clearance of CV8 was 22.5 hours, was the same as AS+Pri (21.8 hours). The inhibitory gametocidel effect on CV8 on P.falciparum has been seen and it help elimination of dissermination. The side effects such as nausea (13.8%), vomitting (4.9%) in CV8 treated groups were the same in AS+Pri groups. These effects were often self-limited. There were no hemoglobinuria case.
Malaria, Primaquine, Malaria, Falciparum

65 patients with uncomplicated Pl.falciparum malaria were monitored during 28 days after 5 -day -course use of artemisinine (year 1998) and 69 patients after 7 day course (year 2001). The mean fever cut time lengthened for 1,5 days in 1998 and 1,8 days in 2001.The mean parasite cut time had lengthened for 1,8 days in1998 and 2,3 days in 2001. The rate of reappearance of parasite accounted for 36,9% within 28 days follow up with 5 -day -course procedure and 7,3 % with 7 days procedure. The rate of repeated infestion was remarkable: 10/21 patients (year1998) and 3/5 (year 2001) had got recurrence. No change of EC50 was reported between the years 1998 and 2001, but an increase by 2 and 4 folds of EC90 and EC99 was reported.EC50,90 and 99% of chloroquine, mefloquine and quinine in the year 2001 decreased by 2 folds vs 1998
malaria ; malaria, falciparum ; Artemisinins ;